|

Asciminib 40 MG Twice Daily Clinical Trials

1 actively recruiting trial across 1 location

Also known as: ABL001

Pipeline

Phase 2: 1

Top Sponsors

  • Medical College of Wisconsin1

Indications

  • Chronic Phase Chronic Myelogenous Leukemia1
  • Cancer1

Detroit, Michigan1 trial

Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

The Barbara Ann Karmanos Cancer Institute

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.